Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease

Rosenson, Robert Sidney
August 2013
Evidence Based Medicine;Aug2013, Vol. 18 Issue 4, p142
Academic Journal
The article presents a commentary on a study performed by B. Mihaylova and colleagues on the effects of lowering low-density lipoprotein (LDL) cholesterol with the statin therapy low risk cardiovascular disease (CVD) patients. It informs that the study included meta-analysis of effects of low-density lipoprotein cholesterol (LDL-C). It mentions that the study showed no evidence for an increased cancer risk or mortality regardless of the potential hazards of the statin therapy.


Related Articles

  • Gender effects of statins.  // Clinical Advisor;Feb2015, Vol. 18 Issue 2, p35 

    No abstract available.

  • Statins reduce risk of major vascular events in low-risk individuals.  // Diabetes Digest;2012, Vol. 11 Issue 3, p178 

    The article reflects on study conducted to determine the effect of lowering Low Density Lipoprotein (LDL) cholesterol on the risk of major vascular events (MVEs) in individuals at low vascular risk and reveals that reduction in risk of MVE was approximately 11 per 1000 over 5 years.

  • What Is the Role of the Clinical Laboratory in the New ACC/AHA Guidelines for the Treatment of Blood Cholesterol in Adults? Jialal, Ishwarlal // American Journal of Clinical Pathology;Jun2014, Vol. 141 Issue 6, p772 

    The article focuses on the guidelines issued by a panel of the American College of Cardiology (ACC and the American Heart Association (AHA) for the treatment of blood cholesterol aimed at reducing adult atherosclerotic cardiovascular risks. Topics discussed include the groups of patients taking...

  • Statins play a crucial role in the fight against coronary heart disease. Tatoulis, James // Journal of Pharmacy Practice & Research;Dec2013, Vol. 43 Issue 4, p332 

    A response by James Tatoulis to a letter to the editor about the article on the unbalanced reporting of the "Catalyst" program and exposure to unconventional views on coronary heart disease (CHD) and cholesterol is presented.

  • Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles. Gardner, Andrew W.; Alaupovic, Petar; Parker, Donald E.; Montgomery, Polly S.; Esponda, Omar L.; Casanegra, Ana I. // International Journal of Vascular Medicine;2013, p1 

    Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared...

  • HDL-C rise: The effect on cardiovascular events. Vora, Jiten // Diabetes Digest;2012, Vol. 11 Issue 3, p172 

    The author discusses the risks of cardiovascular disease (CVD) and offers therapies including statin therapy for people with high baseline risk of (CVD). He explains the cause of this residual risk is the presence of low high density lipoprotein cholesterol (HDL-C) and elevated triglyceride...

  • Understanding the AHA/ACC's new cholesterol treatment guidelines. Brenneman, Anthony // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2014, Vol. 27 Issue 6, p42 

    No abstract available.

  • An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias. Rached, F H; Chapman, M J; Kontush, A // Clinical Pharmacology & Therapeutics;Jul2014, Vol. 96 Issue 1, p57 

    Cardiovascular diseases (CVDs) are the leading cause of morbidity/mortality worldwide. Dyslipidemia is a major risk factor for premature atherosclerosis and CVD. Lowering low-density-lipoprotein cholesterol (LDL-C) levels is well established as an intervention for the reduction of CVDs. Statins...

  • Results of the 4D study: ten years of follow-up? Wanner, Christoph; Schmidt, Kai-Renke; Krane, Vera // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p274 

    Despite the exceedingly high cardiovascular risk in hemodialysis patients, it is uncertain whether statin regimens lead to clinical benefit in this population. KDIGO (Kidney Disease Improving Global Outcomes) guidelines summarize the evidence, stating that initiation of statin treatment is not...


Read the Article


Sign out of this library

Other Topics